| Identification | Back Directory | [Name]
N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide | [CAS]
1135243-19-4 | [Synonyms]
ML012
VU 0255035
CID24768606
VU0255035 hydrate
N-{3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl}-2,1,3-benz...
N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide
2,1,3-Benzothiadiazole-4-sulfonamide, N-[3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-
N-(3-Oxo-3-(4-(pyridin-4-yl)piperazin-1-yl)propyl)benzo[c][1,2,5]thiadiazole-4-sulfonaMide
N-[3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide hydrate
N-(3-oxo-3-(4-(pyridine-4-yl)piperazin-1-yl)propyl)benzo[c][1,2,5]thiadiazole-4-sulfonamide hydrate | [Molecular Formula]
C18H20N6O3S2 | [MDL Number]
MFCD16875440 | [MOL File]
1135243-19-4.mol | [Molecular Weight]
432.52 |
| Chemical Properties | Back Directory | [Melting point ]
159.7-160.2 °C(Solv: dichloromethane (75-09-2); hexane (110-54-3)) | [Boiling point ]
689.3±65.0 °C(Predicted) | [density ]
1.447±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: >5mg/mL | [form ]
powder | [pka]
8.97±0.50(Predicted) | [color ]
yellow |
| Hazard Information | Back Directory | [Uses]
VU 0255035 is a novel, selective antagonist of M1 mAChRs, which has potential treatment in CNS disorders. | [Definition]
ChEBI: N-[3-oxo-3-(4-pyridin-4-yl-1-piperazinyl)propyl]-2,1,3-benzothiadiazole-4-sulfonamide is a member of pyridines and a member of piperazines. | [Biological Activity]
VU0255035 is the first highly selective antagonist at the orthosteric site of the M1 receptor (75-fold selective for M1 relative to other muscarininc subtypes and devoid of activity at other GPCRsion channelstransporters and kinases). There are no highly selective M1 muscarinic receptor antagonists. The existing non-selective drugs do not permit direct evaluation of the role of M1 receptors in CNS fucntions and do not premit therapeutic targeting of M1 receptors in various disease states in which M1 receptors are implicated (epilepsyParkinsonμs diseaseattention and cognitive disordersdystoniaetc). | [storage]
Store at -20°C |
|
| Company Name: |
BePharm Ltd
|
| Tel: |
400-685-9117 |
| Website: |
www.bepharm.com |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|